Navigation Links
Arstasis Launches New AXERA™ Access Device in the U.S.
Date:5/16/2011

REDWOOD CITY, Calif., May 16, 2011 /PRNewswire/ -- Arstasis is pleased to announce the U.S. launch of its latest commercial product - the AXERA™ Access Device.  The AXERA Device enhances insertability into the femoral artery and overall procedural usage while continuing to deliver the clinical benefits of the implant-free Arstaotomy Procedure.

Since 1959, physicians have been using the Modified Seldinger Technique for femoral artery access.  At the end of every such case, patients are left with a substantial hole in the femoral artery which can command significant effort and cath lab resources to close.  The AXERA™ Access Device is a breakthrough femoral artery access tool that quickly creates a longer and shallower angle arteriotomy, the Arstaotomy, resulting in significant tissue-upon-tissue overlap through the artery. Upon sheath removal at the end of the procedure, arterial pressure is decreased across this longer Arstaotomy channel intended to provide an excellent environment for clot formation and rapid femoral artery hemostasis.

The AXERA Device's Arstaotomy Procedure requires only minimal manual compression to provide secure closure with no foreign body implants - eliminating the risk of infections and thromboembolic events related to a vascular implant. The Arstaotomy Procedure promotes rapid hemostasis resulting in excellent patient comfort with decreased bed rest and quicker ambulation.

"The AXERA Access Device delivers a truly unique way to gain access into the femoral artery for diagnostic and cath-possible procedures," commented Dale Wortham, MD from the University of Tennessee Medical Center, Knoxville.  "Unlike vascular closure implants, the AXERA Device delivers rapid arterial hemostasis but does not deposit any foreign material into the patient.  Our results have been excellent with patients generally sitting up in 15 minutes and ambulating in 1 hour.  It really has improved our cath lab throughput and patient satisfaction."

Physicians have also been noting that the new AXERA Device allows them to perform Arstaotomy procedures in almost all patients, instead of having to potentially exclude patients with complex anatomy.  "In my opinion, all patients are candidates for the AXERA Access Device.  The new AXERA Device is sturdier and allows me to more easily gain femoral artery access, even in the more complicated patient subsets of the obese and those with heavily diseased vessels," said Dr. Greg Sampognaro, a practicing interventional cardiologist at the P&S Surgical Hospital in Monroe, Louisiana.

Patient enrollment continues in the RECITAL study, a multi-center, prospective registry that is overseen by a medical monitor and anticipated to enroll up to 500 patients in at least seven U.S. hospitals.

ABOUT ARSTASIS, INC.

Arstasis, Inc., headquartered in Redwood City, California, is a medical device manufacturer dedicated to bringing innovative arterial access devices to cardiologists, interventional radiologists, their staffs, and patients.  Detailed information about the AXERA Access Device and the Arstaotomy procedure is available at www.arstasis.com.

INVESTOR/MEDIA CONTACT
Alexander Arrow, CFO
(650) 508-1549
investorrelations@arstasis.com


'/>"/>
SOURCE Arstasis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
5. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... Mich. , July 13, 2017  Centurion Medical Products, a ... its DisImpactor ® fecal impaction removal device for hospice patient ... ... Patient pain management and ... for Hospice can help alleviate patient pain while preventing unneeded emergency ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners is ... continued efforts to provide innovative offerings to their healthcare partners. These solutions will ... dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent Management ...
(Date:7/26/2017)... ... ... may be hard to imagine that the basic necessities that developed countries take for ... developed countries consider rare or eradicated, like measles, are still a rite of passage ... segment of "Success Files", actor Rob Lowe will introduce a new segment that will ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... will host its 2017 Process Validation and Process Validation Statistics Conferences in ... to process validation lifecycle challenges faced by process validation professionals and statisticians ...
(Date:7/26/2017)... Newport Beach, CA 92660 (PRWEB) , ... ... ... of Data Loss Prevention for on-premises, off and in the cloud ; today ... intelligent detection and scientific algorithms within a simple to use control console for ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
Breaking Medicine News(10 mins):